Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.44 |
| ▸ | HTR7 | P34969 | 5/20 | 0.37 |
| ▸ | HRH2 | P25021 | 5/20 | 0.35 |
| ▸ | HRH1 | P35367 | 5/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | PDCD1LG2 | Q9BQ51 | 3/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6960555 | 0.93 | LTA4H (0.43) | LTA4HHTR7HTR1ADRD2 | |
| SCHEMBL6980220 | 0.85 | LTA4H (0.48) | LTA4HHTR7HRH2HRH1HTR1A | |
| SCHEMBL6980286 | 0.82 | LTA4H (0.52) | LTA4HHTR7HRH2HRH1PDCD1LG2 | |
| SCHEMBL6960535 | 0.79 | CHRM2 (0.30) | — | |
| SCHEMBL6958037 | 0.79 | LTA4H (0.42) | LTA4H | |
| SCHEMBL6959774 | 0.79 | HTR1A (0.36) | HTR7HTR1ADRD2HTR6 | |
| SCHEMBL6959771 | 0.78 | KCNA3 (0.32) | HRH2HRH1HRH3 | |
| SCHEMBL6955686 | 0.77 | GNAI3 (0.34) | HRH2HRH1HRH3 | |
| SCHEMBL6959283 | 0.77 | HTR1A (0.38) | HRH2HRH1HTR1AHRH3 | |
| SCHEMBL6961257 | 0.76 | PIK3CD (0.41) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | LTA4H 4734/4885HTR7 179/4885HRH2 138/4885 |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | LTA4H 4734/4885HTR7 179/4885HRH2 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.